KR100527985B1 - 신속 발현 제제 - Google Patents
신속 발현 제제 Download PDFInfo
- Publication number
- KR100527985B1 KR100527985B1 KR10-2002-7009679A KR20027009679A KR100527985B1 KR 100527985 B1 KR100527985 B1 KR 100527985B1 KR 20027009679 A KR20027009679 A KR 20027009679A KR 100527985 B1 KR100527985 B1 KR 100527985B1
- Authority
- KR
- South Korea
- Prior art keywords
- pyridoxine
- minutes
- formulation
- doxylamine succinate
- hydrochloride
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 238000009472 formulation Methods 0.000 title claims abstract description 65
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229960005008 doxylamine succinate Drugs 0.000 claims abstract description 40
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 38
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 36
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims abstract description 23
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims abstract description 23
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims abstract description 23
- 239000002702 enteric coating Substances 0.000 claims abstract description 20
- 238000009505 enteric coating Methods 0.000 claims abstract description 20
- 238000004090 dissolution Methods 0.000 claims abstract description 19
- 235000008160 pyridoxine Nutrition 0.000 claims abstract description 18
- 239000011677 pyridoxine Substances 0.000 claims abstract description 18
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 18
- 238000005259 measurement Methods 0.000 claims abstract description 17
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 17
- 239000007884 disintegrant Substances 0.000 claims abstract description 9
- 239000008363 phosphate buffer Substances 0.000 claims abstract description 9
- 239000011230 binding agent Substances 0.000 claims abstract description 7
- 239000000945 filler Substances 0.000 claims abstract description 7
- 239000000314 lubricant Substances 0.000 claims abstract description 7
- 239000003381 stabilizer Substances 0.000 claims abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 235000019793 magnesium trisilicate Nutrition 0.000 claims description 11
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims description 10
- 239000000391 magnesium silicate Substances 0.000 claims description 10
- 229940099273 magnesium trisilicate Drugs 0.000 claims description 10
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 10
- 235000012239 silicon dioxide Nutrition 0.000 claims description 10
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 8
- 206010047700 Vomiting Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000035935 pregnancy Effects 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
- 238000009500 colour coating Methods 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 238000003825 pressing Methods 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 description 16
- 238000006731 degradation reaction Methods 0.000 description 16
- 239000003826 tablet Substances 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 8
- 229960001866 silicon dioxide Drugs 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000008199 coating composition Substances 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- -1 dexrate Chemical compound 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- YFGAFXCSLUUJRG-WCCKRBBISA-M sodium;(2s)-2-amino-5-(diaminomethylideneamino)pentanoate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCCN=C(N)N YFGAFXCSLUUJRG-WCCKRBBISA-M 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101100532097 Vitis rotundifolia RUN1 gene Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- NPUOZEMYDHAAMG-UHFFFAOYSA-N hexamagnesium;trisilicate Chemical class [Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] NPUOZEMYDHAAMG-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005455 polacrilin Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Lubricants (AREA)
- Seal Device For Vehicle (AREA)
- Memory System Of A Hierarchy Structure (AREA)
- Power Steering Mechanism (AREA)
Abstract
Description
성분 | 중량 Mg/Tab. | 중량 %/Tab. | 뱃찌 사이즈 100kg |
독실아민 석시네이트 | 10.0 | 6.9 | 6.897 |
염산 피리독신 | 10.0 | 6.9 | 6.897 |
마그네슘 트리실리케이트 | 26.4 | 18.2 | 18.207 |
마이크로크리스탈린 셀룰로스 PH102 | 90.0 | 62.1 | 62.069 |
소디움 크로스카르멜로스 타잎 A | 3.6 | 2.5 | 2.483 |
마그네슘 스테아레이트 | 4.0 | 2.8 | 2.759 |
실리콘 디옥사이드 NF | 1.0 | 0.7 | 0.690 |
합계: | 145.0 | 100 | 100 |
성분 | 중량 Mg/Tab. | 중량 % | 뱃찌 사이즈 100kg |
실 코트 | |||
오파드리TM클리어YS-1-7472 | 4.82 | 3.33 | 3.327 |
정제수 USP | |||
전체: | 4.82 | 3.33 | 3.3 |
엔테릭 코트 | |||
에스트아크릴TM 30D엔테릭 코팅 용액 | 39.58 | 27.29 | 27.294 |
탈크 USP 200메쉬 | 2.85 | 1.97 | 1.968 |
폴리에틸렌 글리콜 400 USP | 1.20 | 0.83 | 0.826 |
안티폼 1520 | 0.12 | 0.08 | 0.081 |
정제수 USP | |||
전체: | 16.04 | 30.17 | 30.17 |
피니싱 코트 | |||
오파드리TM화이트YS-1-7003 | 1.61 | 1.11 | 1.108 |
정제수 USP | |||
전체: | 1.61 | 1.11 | 1.11 |
염산 피리독신 | 런(RUN)1 | 런2 | 런3 | 런4 | 런5 | 런6 | 평균 |
5분 | 20 | 2 | 0 | 77 | 79 | 79 | 43 |
10분 | 91 | 90 | 90 | 91 | 94 | 95 | 92 |
15분 | 96 | 96 | 94 | 94 | 95 | 96 | 95 |
30분 | 95 | 98 | 96 | 95 | 98 | 96 | 96 |
45분 | 97 | 96 | 97 | 94 | 99 | 98 | 97 |
독실아민 석시네이트 | 런1 | 런2 | 런3 | 런4 | 런5 | 런6 | 평균 |
5분 | 17 | 2 | 0 | 70 | 75 | 76 | 40 |
10분 | 90 | 87 | 89 | 89 | 97 | 96 | 91 |
15분 | 98 | 97 | 96 | 92 | 98 | 97 | 96 |
30분 | 97 | 98 | 96 | 94 | 99 | 97 | 97 |
45분 | 98 | 96 | 98 | 92 | 100 | 99 | 97 |
성분 | 중량 Mg/Tab. | 중량 %/Tab. |
독실아민 석시네이트 | 10.5 | 7.2 |
염산 피리독신 | 10.5 | 7.2 |
마그네슘 트리실리케이트 | 30. | 20.6 |
마이크로크리스탈린 셀룰로스 PH102 | 65.0 | 44.5 |
칼슘 포스페이트(이염기) | 25.0 | 17.1 |
마그네슘 스테아레이트 | 4.0 | 2.7 |
콜로이드 실리콘 디옥사이드 | 1.0 | 0.7 |
합계: | 146.0 | 100 |
성분 | 중량/타블렛(Mg) |
오파드리TM 화이트 YS-1-7003 | 4.38 |
안티폼(Antifoam) AF 에멀젼 | 0.07 |
슈레테릭(Sureteric) YAE-6-18107 | 16.06 |
정제수 USP | |
오파드리TM 클리어 YS-1-7472 | 0.73 |
염산 피리독신 | 런1 | 런2 | 런3 | 런4 | 런5 | 런6 | 평균 |
15분 | 17 | 13 | 25 | 31 | 17 | 22 | 21 |
30분 | 31 | 28 | 60 | 63 | 36 | 43 | 43 |
45분 | 51 | 45 | 78 | 80 | 55 | 60 | 61 |
60분 | 69 | 64 | 88 | 89 | 67 | 72 | 75 |
75분 | 79 | 76 | 94 | 94 | 77 | 81 | 83 |
90분 | 84 | 84 | 97 | 97 | 83 | 87 | 89 |
105분 | 88 | 89 | 98 | 99 | 87 | 90 | 92 |
120분 | 91 | 93 | 98 | 98 | 89 | 92 | 93 |
독실아민 석시네이트 | 런1 | 런2 | 런3 | 런4 | 런5 | 런6 | 평균 |
15분 | 16 | 14 | 22 | 31 | 47 | 61 | 32 |
30분 | 31 | 27 | 64 | 63 | 38 | 40 | 44 |
45분 | 47 | 44 | 75 | 79 | 58 | 61 | 61 |
60분 | 71 | 61 | 90 | 85 | 68 | 74 | 75 |
75분 | 76 | 71 | 96 | 89 | 81 | 82 | 82 |
90분 | 85 | 80 | 101 | 88 | 83 | 81 | 86 |
105분 | 92 | 86 | 103 | 95 | 93 | 92 | 93 |
120분 | 93 | 88 | 101 | 96 | 96 | 95 | 95 |
성분 | 중량 Mg/Tab. | 중량 %/Tab. |
염산 피리독신 | 11.0 | 7.5 |
독실아민 석시네이트 | 10.2 | 7.0 |
락토스 NF | 25.0 | 17.1 |
마이크로크리스탈린 셀룰로스 NF | 65.0 | 44.4 |
마그네슘 트리실리케이트 | 30.0 | 20.6 |
실리콘 디옥사이드 | 1.0 | 0.7 |
마그네슘 스테아레이트 | 4.0 | 2.7 |
합계: | 146.2 | 100 |
성분 |
코팅용액 No. 714 |
코팅분말No. 303 |
C.A.P.용액 10% |
C.A.P.용액 5% |
젤라틴용액 No. 105 |
더스팅 분말No. 755 |
화이트 스무씽 시럽 |
슈가 시럽No. 111 |
오팔럭스 AS-7000-B 화이트 |
왁스용액 No. 723 |
염산 피리독신 | 런1 | 런2 | 런3 | 런4 | 런5 | 런6 | 평균 |
15분 | 9 | 11 | 18 | 11 | 16 | 12 | 13 |
30분 | 22 | 23 | 32 | 25 | 28 | 23 | 25 |
45분 | 37 | 34 | 45 | 39 | 42 | 34 | 38 |
60분 | 50 | 44 | 56 | 49 | 51 | 44 | 49 |
90분 | 69 | 63 | 73 | 69 | 67 | 63 | 67 |
120분 | 83 | 76 | 84 | 82 | 80 | 76 | 80 |
150분 | 94 | 86 | 91 | 91 | 86 | 86 | 89 |
180분 | 99 | 94 | 98 | 96 | 93 | 92 | 95 |
240분 | 93 | 93 | 100 | 100 | 99 | 101 | 98 |
독실아민 석시네이트 | 런1 | 런2 | 런3 | 런4 | 런5 | 런6 | 평균 |
15분 | 12 | 15 | 17 | 8 | 18 | 16 | 14 |
30분 | 17 | 21 | 31 | 18 | 27 | 30 | 24 |
45분 | 24 | 32 | 45 | 25 | 38 | 38 | 34 |
60분 | 34 | 41 | 56 | 36 | 46 | 49 | 44 |
90분 | 52 | 55 | 69 | 55 | 62 | 66 | 60 |
120분 | 69 | 65 | 75 | 68 | 71 | 75 | 71 |
150분 | 80 | 74 | 80 | 78 | 79 | 82 | 79 |
180분 | 82 | 78 | 86 | 82 | 80 | 84 | 82 |
240분 | 95 | 89 | 89 | 82 | 80 | 87 | 87 |
Claims (18)
- 외부가 엔테릭 코팅으로 둘러싸여진 핵을 포함하며, 상기 핵은 염산 피리독신과 독실아민 석시네이트를 포함하는 활성 성분 및 붕괴제를 포함하며, pH 6.8 및 37℃로 1000ml 인산염 완충액에서 100rpm으로 타입 2 용해 장치(type 2 dissolution apparatus)(United States Pharmacopeia)에서 측정될 때 하기의 용해 특성을 만족하는 것을 특징으로 하는 신속 발현 제형.(a) 각 염산 피리독신 및 독실아민 석시네이트의 전체량의 적어도 40%는 측정 30분 후 용해됨;(b) 각 염산 피리독신 및 독실아민 석시네이트의 전체량의 적어도 70%는 측정 60분 후 용해됨;(c) 각 염산 피리독신 및 독실아민 석시네이트의 전체량의 적어도 80%는 측정 90분 후 용해됨;(d) 각 염산 피리독신 및 독실아민 석시네이트의 전체량의 적어도 90%는 측정 120분 후 용해됨.
- 제 1항에 있어서, pH 6.8 및 37℃로 1000ml 인산염 완충액에서 100rpm으로 타입 2 용해 장치(type 2 dissolution apparatus)(United States Pharmacopeia)에서 측정될 때 하기의 용해 특성도 만족하는 것을 특징으로 하는 신속 발현 제형.(a) 각 염산 피리독신 및 독실아민 석시네이트의 전체량의 적어도 20%는 측정 15분 후 용해됨;(b) 각 염산 피리독신 및 독실아민 석시네이트의 전체량의 적어도 60%는 측정 45분 후 용해됨;(c) 각 염산 피리독신 및 독실아민 석시네이트의 전체량의 적어도 80%는 측정 75분 후 용해됨.
- 제 1항 또는 제 2항에 있어서, pH 6.8 및 37℃로 1000ml 인산염 완충액에서 100rpm으로 타입 2 용해 장치(type 2 dissolution apparatus)(United States Pharmacopeia)에서 측정될 때 각 염산 피리독신 및 독실아민 석시네이트의 전체량의 적어도 40%는 5분 안에 용해되는 신속 발현 제형.
- 제 1항 또는 제 2항에 있어서, 상기 제형은 적어도 하나의 엔테릭 코팅으로 도포된 핵을 함유하며, 상기 핵은 염산 피리독신, 독실아민 석시네이트 및 다음의 비활성 부형제:충진제 또는 결합제, 붕괴제, 윤활제, 실리카 유동 조정제 및 안정화제를 포함하는 신속 발현 제형.
- 제 4항에 있어서, 상기 충진제 또는 결합제는 마이크로크리스탈린 셀룰로스로 구성되는 신속 발현 제형.
- 제 4항에 있어서, 상기 붕괴제는 소디움 크로스카르멜로스로 구성되는 신속 발현 제형.
- 제 4항에 있어서, 상기 윤활제는 마그네슘 스테아레이트로 구성되는 신속 발현 제형.
- 제 4항에 있어서, 상기 실리카 유동 조정제는 실리콘 디옥사이드로 구성되는 신속 발현 제형.
- 제 4항에 있어서, 상기 안정화제는 마그네슘 트리실리케이트로 구성되는 신속 발현 제형.
- 제 1항 또는 제 2항에 있어서, 상기 핵은:a) 4-10중량%의 염산 피리독신;b) 4-10중량%의 독실아민 석시네이트;c) 40-80중량%의 마이크로크리스탈린 셀룰로스;d) 10-30중량%의 마그네슘 트리실리케이트;e) 0.5-5중량%의 실리콘 디옥사이드;f) 0.5-5중량%의 소디움 크로스카르멜로스; 및g) 0.5-5중량%의 마그네슘 스테아레이트를 포함하는 신속 발현 제형.
- 제 10항에 있어서, 상기 핵은:a) 7중량%의 염산 피리독신;b) 7중량%의 독실아민 석시네이트;c) 62중량%의 마이크로크리스탈린 셀룰로스;d) 18중량%의 마그네슘 트리실리케이트;e) 1중량%의 실리콘 디옥사이드;f) 3중량%의 소디움 크로스카르멜로스; 및g) 3중량%의 마그네슘 스테아레이트를 포함하는 신속 발현 제형.
- 제 4항에 있어서, 상기 엔테릭 코팅은 수용성 원료로 형성되는 신속 발현 제형.
- 제 12항에 있어서, 상기 엔테릭 코팅은 핵에 적용된 실 코트(seal coat)로 구성되고, 엔테릭 코팅 그 자체는 실 코트에 적용되고, 미각적인 탑 코트는 엔테릭 코팅 그 자체 위에 적용되는 신속 발현 제형.
- 척추동물에 있어 메스꺼움 및 구토의 증상을 완화하기 위한 제 1항 또는 제 2항의 신속 발현 제형.
- 인간의 임신 기간중에 메스꺼움 및 구토의 증상을 완화하기 위한 제 1항 또는 제 2항의 신속 발현 제형.
- 필수적으로 제 4항의 제형으로 구성되는 메스꺼움 및 구토와 연관된 증상을 완화하는 치료제.
- ㆍ전 혼합물을 얻기 위해 상기 독실아민 석시네이트 및 상기 실리카 유동 조정제를 혼합하는 단계;ㆍ활성 성분 혼합물을 얻기 위해 상기 전 혼합물에 상기 염산 피리독신을 혼합하는 단계;ㆍ최종 산물을 얻기 위해 상기 활성 성분 혼합물을 상기 잔여 비활성 부형데, 즉 충진제 또는 결합제, 붕괴제, 윤활제, 및 안정화제를 혼합하는 단계; 및ㆍ상기 최종 혼합물을 정제화 및 코팅하는 단계를 포함하는 청구항 4의 신속 발현 제형의 제조방법.
- 제 17항에 있어서, 상기 최종 정제화 및 코팅하는 단계는 상기 최종물을 타블렛 모양으로 압착, 상기 타블렛 모양의 실 코팅, 엔테릭 코팅, 및 컬러 코팅을 포함하는 신속 발현 제형의 제조방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002350195A CA2350195C (en) | 2000-12-20 | 2000-12-20 | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
PCT/CA2001/000951 WO2003000263A1 (en) | 2000-12-20 | 2001-06-21 | Rapid onset formulation |
US09/885,051 US6340695B1 (en) | 2000-12-20 | 2001-06-21 | Rapid onset formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030023612A KR20030023612A (ko) | 2003-03-19 |
KR100527985B1 true KR100527985B1 (ko) | 2005-11-09 |
Family
ID=42104724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-7009679A KR100527985B1 (ko) | 2000-12-20 | 2001-06-21 | 신속 발현 제제 |
Country Status (35)
Country | Link |
---|---|
US (1) | US6340695B1 (ko) |
EP (1) | EP1397133B1 (ko) |
JP (1) | JP4242763B2 (ko) |
KR (1) | KR100527985B1 (ko) |
CN (1) | CN1229112C (ko) |
AT (1) | ATE307582T1 (ko) |
AU (1) | AU2001272243B2 (ko) |
BE (1) | BE1014929A4 (ko) |
BR (1) | BR0107371A (ko) |
CA (1) | CA2350195C (ko) |
DE (2) | DE10196426T1 (ko) |
DK (2) | DK1397133T3 (ko) |
EG (1) | EG24483A (ko) |
ES (1) | ES2251494T3 (ko) |
FI (1) | FI117961B (ko) |
FR (1) | FR2826277B1 (ko) |
GB (1) | GB2383751C (ko) |
GR (1) | GR1004371B (ko) |
HK (1) | HK1052654A1 (ko) |
HU (1) | HU227003B1 (ko) |
IL (1) | IL150349A0 (ko) |
IS (1) | IS2225B (ko) |
IT (1) | ITTO20020524A1 (ko) |
LU (1) | LU90934B1 (ko) |
MC (1) | MC200059A1 (ko) |
MX (1) | MXPA02006037A (ko) |
MY (1) | MY132786A (ko) |
NL (1) | NL1020895C2 (ko) |
NO (1) | NO332190B1 (ko) |
PL (1) | PL204507B1 (ko) |
SE (1) | SE526307C2 (ko) |
TR (1) | TR200201685T1 (ko) |
UA (1) | UA74807C2 (ko) |
UY (1) | UY27352A1 (ko) |
WO (1) | WO2003000263A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101831570B1 (ko) | 2014-08-29 | 2018-02-22 | 듀체스나이 아이엔씨 | 독실아민 및 피리독신 및/또는 이들의 대사 물질 또는 염의 다봉형 방출 제형 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2350195C (en) * | 2000-12-20 | 2003-06-10 | Duchesnay Inc. | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
US8257746B2 (en) | 2001-04-10 | 2012-09-04 | Pernix Therapeutics, Llc | Tannate compositions, methods of making and methods of use |
US8012506B2 (en) * | 2001-04-10 | 2011-09-06 | Pernix Therapeutics, Llc | Tannate compositions, methods of making and methods of use |
ES2229876B1 (es) * | 2001-06-26 | 2006-03-01 | Duchesnay Inc. | Formulacion de accion rapida. |
CA2392486A1 (en) * | 2002-07-05 | 2002-12-08 | Duchesnay Inc. | Pharmaceutical dosage form bearing pregnancy-friendly indicia |
CA2406592C (en) * | 2002-10-04 | 2003-09-30 | Duchesnay Inc. | Method of preparing pharmaceutical dosage forms containing multiple active ingredients |
JP2004231520A (ja) * | 2003-01-28 | 2004-08-19 | Nichiko Pharmaceutical Co Ltd | 保存安定性及び溶出速度に優れた医薬組成物 |
US20050004181A1 (en) * | 2003-07-03 | 2005-01-06 | Duchesnay Inc. | Use of anti-emetic for pre and post operative care |
EP1830886B1 (en) | 2004-12-27 | 2016-04-13 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
CN101166543B (zh) * | 2005-04-28 | 2014-07-16 | 卫材R&D管理有限公司 | 含抗痴呆药物的组合物 |
US20070277530A1 (en) * | 2006-05-31 | 2007-12-06 | Constantin Alexandru Dinu | Inlet flow conditioner for gas turbine engine fuel nozzle |
CN102108059B (zh) * | 2010-09-03 | 2012-05-09 | 合肥工业大学 | 一种琥珀酸多西拉敏的合成方法 |
US8950188B2 (en) | 2011-09-09 | 2015-02-10 | General Electric Company | Turning guide for combustion fuel nozzle in gas turbine and method to turn fuel flow entering combustion chamber |
SG11201403931YA (en) | 2012-02-22 | 2014-08-28 | Duchesnay Inc | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
WO2013123569A1 (en) * | 2012-02-22 | 2013-08-29 | Duchesnay Inc. | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
US10952968B2 (en) | 2012-05-14 | 2021-03-23 | Shionogi & Co., Ltd. | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
US9452181B2 (en) | 2013-07-22 | 2016-09-27 | Duchesnay Inc. | Composition for the management of nausea and vomiting |
EP3024466B1 (en) * | 2013-07-22 | 2018-04-04 | Duchesnay Inc. | Composition for the management of nausea and vomiting |
CN103432126A (zh) * | 2013-08-05 | 2013-12-11 | 北京阜康仁生物制药科技有限公司 | 一种治疗孕吐的药物组合物 |
TWI595874B (zh) | 2014-08-29 | 2017-08-21 | 達契斯奈股份有限公司 | 多西拉敏及吡哆醇及/或其代謝產物或鹽之多模式釋放調配物 |
WO2017029573A1 (en) | 2015-08-17 | 2017-02-23 | Aequus Pharmaceuticals Inc. | Transdermal delivery of doxylamine succinate and pyridoxine hydrochloride |
CN105510512B (zh) * | 2016-01-25 | 2018-06-29 | 南京济群医药科技股份有限公司 | 一种琥珀酸多西拉敏有关物质的rt-hplc检测方法 |
ES2847648T3 (es) * | 2018-09-27 | 2021-08-03 | Inibsa Ginecologia S A | Procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina |
CN114099450A (zh) * | 2020-08-31 | 2022-03-01 | 长春海悦药业股份有限公司 | 一种比拉斯汀片及其制备方法 |
AU2021225255B1 (en) * | 2021-09-03 | 2022-06-16 | Patel, Mihir MR | Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2085641A1 (en) * | 1970-04-20 | 1971-12-31 | Investigations Sci Pharm | Noramidopyrine doxylamine succinate compsn - antiinflammatories analgesics and antipyretics |
US4642231A (en) * | 1983-07-20 | 1987-02-10 | Warner-Lambert Company | Magnesium trisilicate suitable for preparation of medicament adsorbates of antihistamines |
EP0620728B1 (en) * | 1992-01-13 | 1997-01-08 | Pfizer Inc. | Preparation of tablets of increased strength |
CA2139896C (en) * | 1995-01-10 | 2000-03-28 | Don B. Mcdonah | Use of antinauseant agent for terminally ill humans |
US6013280A (en) * | 1997-10-07 | 2000-01-11 | Fuisz Technologies Ltd. | Immediate release dosage forms containing microspheres |
WO2001019901A2 (en) * | 1999-09-14 | 2001-03-22 | Smithkline Beecham Corporation | Process for making aqueous coated beadlets |
CA2350195C (en) * | 2000-12-20 | 2003-06-10 | Duchesnay Inc. | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
-
2000
- 2000-12-20 CA CA002350195A patent/CA2350195C/en not_active Expired - Lifetime
-
2001
- 2001-06-21 HU HU0301950A patent/HU227003B1/hu unknown
- 2001-06-21 IL IL15034901A patent/IL150349A0/xx active IP Right Grant
- 2001-06-21 DE DE10196426T patent/DE10196426T1/de not_active Ceased
- 2001-06-21 DE DE60114475T patent/DE60114475T2/de not_active Expired - Lifetime
- 2001-06-21 BR BR0107371-0A patent/BR0107371A/pt not_active Application Discontinuation
- 2001-06-21 PL PL362763A patent/PL204507B1/pl unknown
- 2001-06-21 GB GB0213990A patent/GB2383751C/en not_active Expired - Lifetime
- 2001-06-21 EP EP01951259A patent/EP1397133B1/en not_active Expired - Lifetime
- 2001-06-21 AU AU2001272243A patent/AU2001272243B2/en not_active Expired
- 2001-06-21 US US09/885,051 patent/US6340695B1/en not_active Expired - Lifetime
- 2001-06-21 MX MXPA02006037A patent/MXPA02006037A/es active IP Right Grant
- 2001-06-21 JP JP2003506908A patent/JP4242763B2/ja not_active Expired - Fee Related
- 2001-06-21 ES ES01951259T patent/ES2251494T3/es not_active Expired - Lifetime
- 2001-06-21 AT AT01951259T patent/ATE307582T1/de active
- 2001-06-21 TR TR2002/01685T patent/TR200201685T1/xx unknown
- 2001-06-21 KR KR10-2002-7009679A patent/KR100527985B1/ko active IP Right Review Request
- 2001-06-21 UA UA2002065093A patent/UA74807C2/uk unknown
- 2001-06-21 WO PCT/CA2001/000951 patent/WO2003000263A1/en active IP Right Grant
- 2001-06-21 DK DK01951259T patent/DK1397133T3/da active
- 2001-06-21 CN CNB018145485A patent/CN1229112C/zh not_active Expired - Fee Related
-
2002
- 2002-06-07 IS IS6412A patent/IS2225B/is unknown
- 2002-06-12 GR GR20020100280A patent/GR1004371B/el unknown
- 2002-06-18 NL NL1020895A patent/NL1020895C2/nl not_active IP Right Cessation
- 2002-06-18 IT IT2002TO000524A patent/ITTO20020524A1/it unknown
- 2002-06-19 MY MYPI20022296A patent/MY132786A/en unknown
- 2002-06-19 EG EG2002060693A patent/EG24483A/xx active
- 2002-06-20 MC MC2486A patent/MC200059A1/xx unknown
- 2002-06-20 NO NO20022982A patent/NO332190B1/no not_active IP Right Cessation
- 2002-06-20 DK DK200200947A patent/DK176018B1/da not_active IP Right Cessation
- 2002-06-20 FR FR0207643A patent/FR2826277B1/fr not_active Expired - Lifetime
- 2002-06-20 BE BE2002/0397A patent/BE1014929A4/fr not_active IP Right Cessation
- 2002-06-21 LU LU90934A patent/LU90934B1/fr active
- 2002-06-21 UY UY27352A patent/UY27352A1/es not_active Application Discontinuation
- 2002-07-03 SE SE0202061A patent/SE526307C2/sv unknown
- 2002-09-25 FI FI20021708A patent/FI117961B/fi not_active IP Right Cessation
-
2003
- 2003-07-11 HK HK03105025A patent/HK1052654A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101831570B1 (ko) | 2014-08-29 | 2018-02-22 | 듀체스나이 아이엔씨 | 독실아민 및 피리독신 및/또는 이들의 대사 물질 또는 염의 다봉형 방출 제형 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100527985B1 (ko) | 신속 발현 제제 | |
AU2001272243A1 (en) | Rapid onset formulation | |
US20200085861A1 (en) | Pharmaceutical formulations of nitrite and uses thereof | |
JPWO2008129846A1 (ja) | 医薬組成物 | |
EP3162363B1 (en) | Composite preparation comprising active ingredient-containing film coating layer | |
AU2012357956A1 (en) | Immediate release multi unit pellet system | |
TWI592154B (zh) | Allisartan-based solid dispersions and pharmaceutical compositions containing the solid dispersions | |
WO2009027786A2 (en) | Matrix dosage forms of varenicline | |
KR102165548B1 (ko) | 두타스테라이드가 봉입된 나노 가용화 다공체, 이를 포함하는 약학 조성물 및 이의 제조방법 | |
EP3925601A1 (en) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor | |
US20180344648A1 (en) | Clobazam tablet formulation and process for its preparation | |
US20110262540A1 (en) | Solid Pharmaceutical Composition Comprising Exemestane | |
US20050171119A1 (en) | Pharmaceutical formulations with modified release | |
RU2266744C2 (ru) | Композиция быстрого начала действия | |
EP3087978A1 (en) | Sustained-release pharmaceutical composition containing acebrophylline and hydrophillic sustained-release agent | |
JP2007302688A (ja) | 速効性処方剤 | |
EP3251669B1 (en) | Solid composition of pyrrole carboxamide | |
KR20240019293A (ko) | 습기 감응성 약학 조성물용 보호 코팅 | |
KR101591357B1 (ko) | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 | |
IE83699B1 (en) | Rapid onset formulation | |
TR2022013349A2 (tr) | Li̇nagli̇pti̇n i̇hti̇va eden farmasöti̇k kompozi̇syonlar | |
EP4356904A1 (en) | A capsule comprising lansoprazole | |
ZA200300594B (en) | Rapid onset formulation. | |
NZ519709A (en) | Rapid onset formulation comprising pyridoxine HCL and doxylamine succinate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120814 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20130913 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140916 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160822 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170921 Year of fee payment: 13 |
|
J204 | Request for invalidation trial [patent] | ||
FPAY | Annual fee payment |
Payment date: 20180809 Year of fee payment: 14 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2018100002127; TRIAL DECISION FOR INVALIDATION REQUESTED 20180710 Effective date: 20190509 |
|
J202 | Request for trial for correction [limitation] | ||
FPAY | Annual fee payment |
Payment date: 20190917 Year of fee payment: 15 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2019105000080; TRIAL DECISION FOR CORRECTION REQUESTED 20190816 Effective date: 20201027 |
|
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J122 | Written withdrawal of action (patent court) |